stoxline Quote Chart Rank Option Currency Glossary
  
Bio-Techne Corporation (TECH)
70.39  0.97 (1.4%)    03-28 16:00
Open: 69.89
High: 70.765
Volume: 1,122,748
  
Pre. Close: 69.42
Low: 69.28
Market Cap: 11,065(M)
Technical analysis
2024-03-28 4:54:37 PM
Short term     
Mid term     
Targets 6-month :  87.2 1-year :  91.97
Resists First :  74.66 Second :  78.75
Pivot price 71.88
Supports First :  68.05 Second :  56.61
MAs MA(5) :  69.78 MA(20) :  72.63
MA(100) :  69.75 MA(250) :  74.19
MACD MACD :  -0.7 Signal :  -0.2
%K %D K(14,3) :  11.8 D(3) :  8.1
RSI RSI(14): 45.6
52-week High :  89.91 Low :  51.79
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ TECH ] has closed above bottom band by 33.0%. Bollinger Bands are 9.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 70.89 - 71.22 71.22 - 71.53
Low: 68.44 - 68.84 68.84 - 69.2
Close: 69.74 - 70.39 70.39 - 70.98
Company Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Headline News

Thu, 28 Mar 2024
BIO-TECHNE AND NIKON INSTRUMENTS INC. ANNOUNCE PARTNERSHIP TO EXPAND ACCESS TO INNOVATIVE ... - PR Newswire

Wed, 27 Mar 2024
Nordea Investment Management AB Has $815000 Holdings in Bio-Techne Co. (NASDAQ:TECH) - Defense World

Tue, 26 Mar 2024
Fort Washington Investment Advisors Inc. OH Grows Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat

Mon, 25 Mar 2024
Bio-Techne Co. (NASDAQ:TECH) Receives $84.11 Average Target Price from Analysts - MarketBeat

Fri, 22 Mar 2024
BIO-TECHNE RECEIVES EUROPEAN IVDR CERTIFICATION FOR DIAGNOSTIC TEST TO MONITOR CHRONIC ... - PR Newswire

Sat, 02 Mar 2024
What Does Bio-Techne Corporation's (NASDAQ:TECH) Share Price Indicate? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 157 (M)
Shares Float 155 (M)
Held by Insiders 0.9 (%)
Held by Institutions 100.5 (%)
Shares Short 4,580 (K)
Shares Short P.Month 3,320 (K)
Stock Financials
EPS 1.38
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 12.48
Profit Margin 19.5 %
Operating Margin 18.3 %
Return on Assets (ttm) 6.3 %
Return on Equity (ttm) 11.8 %
Qtrly Rev. Growth 0.4 %
Gross Profit (p.s.) 0
Sales Per Share 7.25
EBITDA (p.s.) 2.05
Qtrly Earnings Growth -45.3 %
Operating Cash Flow 276 (M)
Levered Free Cash Flow 163 (M)
Stock Valuations
PE Ratio 50.64
PEG Ratio 5.3
Price to Book value 5.63
Price to Sales 9.7
Price to Cash Flow 40.02
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android